Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $45.66, but opened at $47.62. Definium Therapeutics shares last traded at $46.43, with a volume of 706,068 shares trading hands.

Analyst Ratings Changes

Several brokerages recently issued reports on DFTX. Piper Sandler reissued an “overweight” rating and issued a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. JonesTrading upped their target price on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Needham & Company LLC raised their price target on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Finally, Stifel Nicolaus lifted their price objective on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $49.23.

Definium Therapeutics Stock Up 1.4%

The firm has a market capitalization of $4.62 billion, a price-to-earnings ratio of -18.60 and a beta of 2.20. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average price is $30.57 and its 200 day moving average price is $22.40.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, research analysts forecast that Definium Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider directly owned 320,571 shares in the company, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 48,096 shares of company stock worth $2,165,763 in the last 90 days. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Palumbo Wealth Management LLC grew its position in shares of Definium Therapeutics by 18.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock valued at $522,000 after purchasing an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Definium Therapeutics during the fourth quarter worth approximately $117,000. Bay Rivers Group boosted its stake in Definium Therapeutics by 14.3% during the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after buying an additional 2,000 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Definium Therapeutics in the 3rd quarter valued at $107,000. Finally, Caxton Associates LLP purchased a new stake in Definium Therapeutics in the 3rd quarter valued at $126,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.